Global Nanomedicine Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 1–1,000 nm range, biochips, and polymer therapeutics.
The majority of nanomedicines used now allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and blood–brain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.
The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.
Market Analysis: The “Global Nanomedicine Market” is estimated to witness a CAGR of 17.1% during the forecast period 2017–2023. The nanomedicine market is analyzed based on two segments – therapeutic applications and regions.
Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.
Therapeutic Application Analysis: Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.
Key Players: Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.
Competitive Analysis: At present, the nanomedicine market is at a nascent stage – but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
Benefits: The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
The majority of nanomedicines used now allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and blood–brain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.
The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.
Market Analysis: The “Global Nanomedicine Market” is estimated to witness a CAGR of 17.1% during the forecast period 2017–2023. The nanomedicine market is analyzed based on two segments – therapeutic applications and regions.
Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.
Therapeutic Application Analysis: Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.
Key Players: Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.
Competitive Analysis: At present, the nanomedicine market is at a nascent stage – but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
Benefits: The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Industry Trends
1.3 PEST Analysis
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
3.3.1 mHealth Market
3.3.2 Healthcare Analytics Market
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory Bodies and Standards
4.3 Government Spending and Initiatives
4.4 Porter 5 (Five) Forces
5 MARKET CHARACTERISTICS
5.1 Evolution
5.2 Ecosystem
5.2.1 Regulatory Process
5.2.2 Clinical Trials
5.2.3 Pricing and Reimbursement
5.3 Market Segmentation
5.4 Market Dynamics
5.4.1 Drivers
5.4.1.1 Emergence of nanorobotics
5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments
5.4.1.3 Reasonable investments in R&D
5.4.1.4 Increased support from governments
5.4.2 Restraints
5.4.2.1 Long approval process and stringent regulations
5.4.2.2 Problems regarding nanoscale manufacturing
5.4.2.3 Risks related to nanomedicines
5.4.2.4 Undefined regulatory standards
5.4.3 Opportunities
5.4.3.1 Aging population with chronic care needs
5.4.3.2 Population and income growth in emerging countries
5.4.4 DRO – Impact Analysis
6 TRENDS, ROADMAP AND PROJECTS
6.1 Market Trends and Impact
6.2 Technology Roadmap
7 TYPES: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Global Nanomedicine Market in Oncology Segment
7.3 Global Nanomedicine Market in Cardiovascular Segment
7.4 Global Nanomedicine Market in Neurology Segment
7.5 Global Nanomedicine Market in Anti-inflammatory Segment
7.6 Global Nanomedicine Market in Anti-infective Segment
7.7 Global Nanomedicine Market in Other Therapeutic Areas
8 TRENDING NANOMEDICINES
8.1 Overview
8.2 Abraxane
8.3 Alimta
8.4 Eligard
8.5 Copaxone
8.6 Rapamune
8.7 Neulasta
8.8 Cimzia
8.9 AmBisome
8.10 Mircera
8.11 Pegasys
8.12 Emend
8.13 Renagel
8.14 Ritalin
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.1.1 Global Nanomedicine Market by Geographical Segmentation
9.2 Key Leading Countries
9.2.1 US
9.2.2 Germany
9.2.3 Japan
10 VENDOR SCENARIO
11 VENDOR PROFILES
11.1 Merck & Co. Inc.
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Revenue
11.1.4 Recent Developments
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 Hoffmann-La Roche Ltd.
11.2.1 Overview
11.2.2 Business Unit
11.2.3 Geographic Revenue
11.2.4 Recent Developments
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Gilead Sciences
11.3.1 Overview
11.3.2 Business Unit
11.3.3 Geographic Revenue
11.3.4 Recent Developments
11.3.5 SWOT Analysis
11.3.6 Business strategies
11.4 Novartis AG
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Geographic Revenue
11.4.4 Recent Developments
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Amgen Inc.
11.5.1 Overview
11.5.2 Business Unit
11.5.3 Geographic Revenue
11.5.4 Recent Developments
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 GLOBAL GENERALIST
12.1 Pfizer Inc.
12.1.1 Overview
12.1.2 Recent Developments
12.1.3 Pfizer in 2015
12.2 Eli Lilly and Company
12.2.1 Overview
12.2.2 Recent Developments
12.2.3 Eli Lilly and Company in 2015
12.3 Sanofi
12.3.1 Overview
12.3.2 Recent Developments
12.3.3 Sanofi in 2015
13 COMPANIES TO WATCH FOR
13.1 Nanobiotix SA
13.1.1 Overview
13.1.2 Offering
13.1.3 Recent Developments
13.2 UCB SA
13.2.1 Overview
13.2.2 Offering
13.2.3 Recent Developments
14 MARKET LANDSCAPE
14.1 Market Landscape
14.1.1 Mergers & Acquisitions (M&A)
Annexure
? Abbreviations
Table 1 GLOBAL NANOMEDICINE MARKET REVENUE BY APPLICATION TYPE, 2017-2023 ($BILLION)
Table 2 IOE HEALTHCARE MARKET REVENUE BY TYPE, 2016-2022 ($BILLION)
Table 3 TECHNOLOGIES MARKET REVENUE BY TYPE, 2016-2022 ($BILLION)
Table 4 NETWORK TECHNOLOGIES MARKET REVENUE BY RANGE, 2016-2022 ($BILLION)
Table 5 SHORT RANGE NETWORK TECHNOLOGIES MARKET REVENUE, 2016-2022 ($BILLION)
Table 6 IOT HEALTHCARE MARKET REVENUE BY SERVICES, 2016-2022 ($BILLION)
Table 7 TELEMEDICINE MARKET REVENUE BY TYPE, 2016-2022 ($BILLION)
Table 8 MERCK & CO. INC.: RECENT DEVELOPMENTS
Table 9 HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 10 GILEAD SCIENCES: KEY MEDICINES/PRODUCTS
Table 11 GILEAD SCIENCES: PIPELINE PRODUCTS
Table 12 GILEAD SCIENCES: RECENT DEVELOPMENTS
Table 13 NOVARTIS AG: RECENT DEVELOPMENTS
Table 14 AMGEN INC.: RECENT DEVELOPMENTS
Table 15 PFIZER INC.: RECENT DEVELOPMENTS
Table 16 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 17 MERGER & ACQUISITION, 2014–2015
Chart 1 PEST ANALYSIS OF NANOMEDICINE MARKET
Chart 2 RESEARCH METHODOLOGY OF GLOBAL NANOMEDICINE MARKET
Chart 3 GLOBAL NANOMEDICINE MARKET REVENUE, 2016-2023 ($BILLION)
Chart 4 SHARE OF ENROLLMENT BY VARIOUS INSURANCE PROGRAMS
Chart 5 PORTERS 5 FORCES ON IOT HEALTHCARE MARKET
Chart 6 EVOLUTION OF NANOMEDICINES
Chart 7 ECOSYSTEM OF IOT HEALTHCARE MARKET
Chart 8 IOT HEALTHCARE MARKET SEGMENTATION
Chart 9 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES
Chart 10 DRO - IMPACT ANALYSIS OF IOT HEALTHCARE MARKET
Chart 11 TECHNOLOGY ROADMAP FOR IOT HEALTHCARE MARKET
Chart 12 NANOMEDICINE MARKET BY THERAPEUTIC APPLICATIONS
Chart 13 GLOBAL NANOMEDICINE MARKET SHARE BY THERAPEUTIC APPLICATIONS 2016
Chart 14 GLOBAL NANOMEDICINE MARKET REVENUE IN ONCOLOGY SEGMENT, 2016-2023 ($BILLION)
Chart 15 GLOBAL NANOMEDICINE MARKET REVENUE IN CARDIOVASCULAR SEGMENT, 2016-2023 ($BILLION)
Chart 16 GLOBAL NANOMEDICINE MARKET REVENUE IN NEUROLOGY SEGMENT, 2016-2023 ($BILLION)
Chart 17 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFLAMMATORY SEGMENT, 2016-2023 ($BILLION)
Chart 18 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFECTIVE SEGMENT, 2016-2023 ($BILLION)
Chart 19 GLOBAL NANOMEDICINE MARKET REVENUE IN OTHER THERAPEUTIC SEGMENTS, 2016-2023 ($BILLION)
Chart 20 IOT HEALTHCARE MARKET REVENUE BY TECHNOLOGIES, 2016-2022
Chart 21 SHORT RANGE NETWORK MARKET REVENUE, 2015-2022 ($BILLION)
Chart 22 GEOGRAPHIC REVENUE IN 2016 (%)
Chart 23 MERCK & CO. INC.: OVERVIEW SNAPSHOT
Chart 24 MERCK & CO. INC.: BUSINESS UNITS
Chart 25 GE: GEOGRAPHIC REVENUE
Chart 26 MERCK & CO. INC.: SWOT ANALYSIS
Chart 27 HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
Chart 28 HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS
Chart 29 HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE
Chart 30 HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 31 GILEAD SCIENCES: OVERVIEW SNAPSHOT
Chart 32 GILEAD SCIENCES: BUSINESS UNITS
Chart 33 GILEAD SCIENCES: GEOGRAPHIC REVENUE
Chart 34 GILEAD SCIENCES: SWOT ANALYSIS
Chart 35 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 36 NOVARTIS AG: BUSINESS UNITS
Chart 37 NOVARTIS AG: GEOGRAPHIC REVENUE
Chart 38 NOVARTIS AG: SWOT ANALYSIS
Chart 39 AMGEN INC.: OVERVIEW SNAPSHOT
Chart 40 AMGEN INC.: BUSINESS UNITS
Chart 41 AMGEN INC.: GEOGRAPHIC REVENUE
Chart 42 AMGEN INC.: SWOT ANALYSIS
1.1 Industry Overview
1.2 Industry Trends
1.3 PEST Analysis
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
3.3.1 mHealth Market
3.3.2 Healthcare Analytics Market
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory Bodies and Standards
4.3 Government Spending and Initiatives
4.4 Porter 5 (Five) Forces
5 MARKET CHARACTERISTICS
5.1 Evolution
5.2 Ecosystem
5.2.1 Regulatory Process
5.2.2 Clinical Trials
5.2.3 Pricing and Reimbursement
5.3 Market Segmentation
5.4 Market Dynamics
5.4.1 Drivers
5.4.1.1 Emergence of nanorobotics
5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments
5.4.1.3 Reasonable investments in R&D
5.4.1.4 Increased support from governments
5.4.2 Restraints
5.4.2.1 Long approval process and stringent regulations
5.4.2.2 Problems regarding nanoscale manufacturing
5.4.2.3 Risks related to nanomedicines
5.4.2.4 Undefined regulatory standards
5.4.3 Opportunities
5.4.3.1 Aging population with chronic care needs
5.4.3.2 Population and income growth in emerging countries
5.4.4 DRO – Impact Analysis
6 TRENDS, ROADMAP AND PROJECTS
6.1 Market Trends and Impact
6.2 Technology Roadmap
7 TYPES: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Global Nanomedicine Market in Oncology Segment
7.3 Global Nanomedicine Market in Cardiovascular Segment
7.4 Global Nanomedicine Market in Neurology Segment
7.5 Global Nanomedicine Market in Anti-inflammatory Segment
7.6 Global Nanomedicine Market in Anti-infective Segment
7.7 Global Nanomedicine Market in Other Therapeutic Areas
8 TRENDING NANOMEDICINES
8.1 Overview
8.2 Abraxane
8.3 Alimta
8.4 Eligard
8.5 Copaxone
8.6 Rapamune
8.7 Neulasta
8.8 Cimzia
8.9 AmBisome
8.10 Mircera
8.11 Pegasys
8.12 Emend
8.13 Renagel
8.14 Ritalin
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.1.1 Global Nanomedicine Market by Geographical Segmentation
9.2 Key Leading Countries
9.2.1 US
9.2.2 Germany
9.2.3 Japan
10 VENDOR SCENARIO
11 VENDOR PROFILES
11.1 Merck & Co. Inc.
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Revenue
11.1.4 Recent Developments
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 Hoffmann-La Roche Ltd.
11.2.1 Overview
11.2.2 Business Unit
11.2.3 Geographic Revenue
11.2.4 Recent Developments
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Gilead Sciences
11.3.1 Overview
11.3.2 Business Unit
11.3.3 Geographic Revenue
11.3.4 Recent Developments
11.3.5 SWOT Analysis
11.3.6 Business strategies
11.4 Novartis AG
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Geographic Revenue
11.4.4 Recent Developments
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Amgen Inc.
11.5.1 Overview
11.5.2 Business Unit
11.5.3 Geographic Revenue
11.5.4 Recent Developments
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 GLOBAL GENERALIST
12.1 Pfizer Inc.
12.1.1 Overview
12.1.2 Recent Developments
12.1.3 Pfizer in 2015
12.2 Eli Lilly and Company
12.2.1 Overview
12.2.2 Recent Developments
12.2.3 Eli Lilly and Company in 2015
12.3 Sanofi
12.3.1 Overview
12.3.2 Recent Developments
12.3.3 Sanofi in 2015
13 COMPANIES TO WATCH FOR
13.1 Nanobiotix SA
13.1.1 Overview
13.1.2 Offering
13.1.3 Recent Developments
13.2 UCB SA
13.2.1 Overview
13.2.2 Offering
13.2.3 Recent Developments
14 MARKET LANDSCAPE
14.1 Market Landscape
14.1.1 Mergers & Acquisitions (M&A)
Annexure
? Abbreviations
Table 1 GLOBAL NANOMEDICINE MARKET REVENUE BY APPLICATION TYPE, 2017-2023 ($BILLION)
Table 2 IOE HEALTHCARE MARKET REVENUE BY TYPE, 2016-2022 ($BILLION)
Table 3 TECHNOLOGIES MARKET REVENUE BY TYPE, 2016-2022 ($BILLION)
Table 4 NETWORK TECHNOLOGIES MARKET REVENUE BY RANGE, 2016-2022 ($BILLION)
Table 5 SHORT RANGE NETWORK TECHNOLOGIES MARKET REVENUE, 2016-2022 ($BILLION)
Table 6 IOT HEALTHCARE MARKET REVENUE BY SERVICES, 2016-2022 ($BILLION)
Table 7 TELEMEDICINE MARKET REVENUE BY TYPE, 2016-2022 ($BILLION)
Table 8 MERCK & CO. INC.: RECENT DEVELOPMENTS
Table 9 HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 10 GILEAD SCIENCES: KEY MEDICINES/PRODUCTS
Table 11 GILEAD SCIENCES: PIPELINE PRODUCTS
Table 12 GILEAD SCIENCES: RECENT DEVELOPMENTS
Table 13 NOVARTIS AG: RECENT DEVELOPMENTS
Table 14 AMGEN INC.: RECENT DEVELOPMENTS
Table 15 PFIZER INC.: RECENT DEVELOPMENTS
Table 16 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 17 MERGER & ACQUISITION, 2014–2015
Chart 1 PEST ANALYSIS OF NANOMEDICINE MARKET
Chart 2 RESEARCH METHODOLOGY OF GLOBAL NANOMEDICINE MARKET
Chart 3 GLOBAL NANOMEDICINE MARKET REVENUE, 2016-2023 ($BILLION)
Chart 4 SHARE OF ENROLLMENT BY VARIOUS INSURANCE PROGRAMS
Chart 5 PORTERS 5 FORCES ON IOT HEALTHCARE MARKET
Chart 6 EVOLUTION OF NANOMEDICINES
Chart 7 ECOSYSTEM OF IOT HEALTHCARE MARKET
Chart 8 IOT HEALTHCARE MARKET SEGMENTATION
Chart 9 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES
Chart 10 DRO - IMPACT ANALYSIS OF IOT HEALTHCARE MARKET
Chart 11 TECHNOLOGY ROADMAP FOR IOT HEALTHCARE MARKET
Chart 12 NANOMEDICINE MARKET BY THERAPEUTIC APPLICATIONS
Chart 13 GLOBAL NANOMEDICINE MARKET SHARE BY THERAPEUTIC APPLICATIONS 2016
Chart 14 GLOBAL NANOMEDICINE MARKET REVENUE IN ONCOLOGY SEGMENT, 2016-2023 ($BILLION)
Chart 15 GLOBAL NANOMEDICINE MARKET REVENUE IN CARDIOVASCULAR SEGMENT, 2016-2023 ($BILLION)
Chart 16 GLOBAL NANOMEDICINE MARKET REVENUE IN NEUROLOGY SEGMENT, 2016-2023 ($BILLION)
Chart 17 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFLAMMATORY SEGMENT, 2016-2023 ($BILLION)
Chart 18 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFECTIVE SEGMENT, 2016-2023 ($BILLION)
Chart 19 GLOBAL NANOMEDICINE MARKET REVENUE IN OTHER THERAPEUTIC SEGMENTS, 2016-2023 ($BILLION)
Chart 20 IOT HEALTHCARE MARKET REVENUE BY TECHNOLOGIES, 2016-2022
Chart 21 SHORT RANGE NETWORK MARKET REVENUE, 2015-2022 ($BILLION)
Chart 22 GEOGRAPHIC REVENUE IN 2016 (%)
Chart 23 MERCK & CO. INC.: OVERVIEW SNAPSHOT
Chart 24 MERCK & CO. INC.: BUSINESS UNITS
Chart 25 GE: GEOGRAPHIC REVENUE
Chart 26 MERCK & CO. INC.: SWOT ANALYSIS
Chart 27 HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
Chart 28 HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS
Chart 29 HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE
Chart 30 HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 31 GILEAD SCIENCES: OVERVIEW SNAPSHOT
Chart 32 GILEAD SCIENCES: BUSINESS UNITS
Chart 33 GILEAD SCIENCES: GEOGRAPHIC REVENUE
Chart 34 GILEAD SCIENCES: SWOT ANALYSIS
Chart 35 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 36 NOVARTIS AG: BUSINESS UNITS
Chart 37 NOVARTIS AG: GEOGRAPHIC REVENUE
Chart 38 NOVARTIS AG: SWOT ANALYSIS
Chart 39 AMGEN INC.: OVERVIEW SNAPSHOT
Chart 40 AMGEN INC.: BUSINESS UNITS
Chart 41 AMGEN INC.: GEOGRAPHIC REVENUE
Chart 42 AMGEN INC.: SWOT ANALYSIS
